Crizotinib in the treatment of non-small-cell lung carcinoma
Recent studies have demonstrated the benefit of EGFR tyrosine kinase inhibitors in the treatment of advanced non-small-cell lung cancer (NSCLC). The role of activation of the anaplastic lymphoma kinase (ALK) pathway and the presence of the fusion gene EML4-ALK are new molecular targets in studies in...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Termedia Publishing House
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687470/ |